Author(s): Jishala MI, Venkateswaramurthy N, Sambathkumar R


DOI: 10.5958/0974-360X.2020.00443.6   

Address: Jishala MI, Venkateswaramurthy N*, Sambathkumar R
Department of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy, Kumarapalayam – 638183, Tamil Nadu, India.
*Corresponding Author

Published In:   Volume - 13,      Issue - 5,     Year - 2020

Based on the World Health Organization (WHO) report, in many of the countries, cancer was the first or second most cause for death before 70 years of the age. Nowadays cancer treatment employs better prognosis by attaining improvement in treatment modalities including radiotherapy & systemic therapies to prolong the life of the cancer patient. However in long term survivors frequent cause and important adverse reaction (ADR) of cancer chemotherapy was cardiotoxicity. Thus cancer chemotherapy has complicated by the development of cardiotoxicity such as left ventricular dysfunction/ heart failure, hypertension, thromboembolism, ischemia, bradycardia. Cardiovascular damage caused by the cancer treatment may be the result of accelerated atherosclerosis due to cancer chemotherapy related to cardiovascular risk factors or of damage caused by the treatment itself. Cardiotoxicity can develop in 3 stages such as sub acute, acute and chronic. These effects can occur during the treatment or many years after the completion of the treatment as a result of undiagnosed or subclinical dysfunction. During chemotherapy cardiac dysfunction and the susceptibility of patients to develop cardiotoxicity, mechanisms are scare. To find the long term cardiovascular side effects followed by cancer therapy, clinical trials studies were going nowadays even though a clear mechanism of cardiotoxicity associated to cancer medications was lacking. The aim of the review is to summarize the range of cardiovascular side effects and the possible mechanism of cardiotoxicity associated with each chemotherapeutics agents.

Cite this article:
Jishala MI, Venkateswaramurthy N, Sambathkumar R. Cardiotoxicity associated with Cancer Chemotherapy. Research J. Pharm. and Tech 2020; 13(5):2480-2487. doi: 10.5958/0974-360X.2020.00443.6

Jishala MI, Venkateswaramurthy N, Sambathkumar R. Cardiotoxicity associated with Cancer Chemotherapy. Research J. Pharm. and Tech 2020; 13(5):2480-2487. doi: 10.5958/0974-360X.2020.00443.6   Available on:

1.    Lindsey A, Rebecca L, Elizabeth M, Ahmedin Jemal. Global Cancer Incidence and Mortality Rates and Trends—An Update. Cancer Epidemiol Biomarkers Prev. 2016; 25(1): 16-27
2.    Freddie B, Jacques F, Isabelle Rebecca L, Lindsey A, Ahmedin Jemal. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca cancer j clin. 2018; 68(2): 394–424.
3.    Jingchun S, Qiang W, Yubo Z, Jingqi W, Hua X. A systematic analysis of FDA-approved anticancer drugs. BMC Systems Biology. 2017; 11(5): 27-43.
4.    United Nations Development Programme. Human Development Report 2016: Human Development for Everyone. New York, NY: United Nations Development Programme; 2016.
5.    Borchmann P, Eichenauer D, Engert A. State of the art in the treatment of Hodgkin lymphoma. Nature Reviews Clinical Oncology. 2012; 9(8) :450–459.
6.    Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804): 1707–1716.
7.    Hodgson DC. Late effects in the era of modern therapy for Hodgkin lymphoma. Hematol Am Soc Hematol Educ Prog. 2011; 14(6): 323–329.
8.    Nemes A, Piros GA, Domsik P, Kalapos A, Forster T. Left atrial volumetric and strain analysis by three-dimensional speckletracking echocardiography in noncompaction cardiomyopathy: results from the MAGYAR-path study. Hellenic Journal of Cardiology. 2016; 57(1): 23-29.
9.    Khakoo A, Liu P, Force T. Cardiotoxicity due to cancer therapy. Texas Heart Institute Journal. 2011; 38(3): 253-256.
10.    Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Annals of Oncology. 2010; 21(5): 277–282.
11.    Jiji R, Kramer C, Salerno M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. Journal of Nuclear Cardiology. 2012; 19(2): 377-388.
12.    Seidman A, Hudis C, Pierri M, et al. Cardiac dysfunction in the trastu- zumab clinical trials experience. Journal of Clincal Oncology. 2002; 20(5): 1215-1221
13.    Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010; 9(3): 203–214.
14.    Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs:successes, challenges and opportunities. Molecular Oncology. 2012; 6(2): 155–176.
15.    Kinch MS. An analysis of FDA-approved drugs for oncology. Drug Discoverv Today. 2014; 19(12): 1831–1835.
16.    Blagosklonny MV. Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle. 2004; 3(8): 1035–1042.
17.    Winkler GC, Barle EL, Galati G, Kluwe WM. Functional differentiation of cytotoxic cancer drugs and targeted cancer therapeutics. Regulatory Toxicology and Pharmacol. 2014;70(1):46–53.
18.    Baldo BA, Pham NH. Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer Metastasis and Review. 2013; 32(3–4): 723–761.
19.    Tseng HH, He B. Molecular markers as therapeutic targets in lung cancer. Chinese Journal of cancer. 2013; 32(2): 59–62.
20.    Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. Journal of Clinical Oncology. 2013; 31(15): 1806–1814.
21.    Kummar S, Chen HX, Wright J, et al. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nature Review Drug Discoverv. 2010; 9(11): 843–856.
22.    Kwak EL, Clark JW, Chabner B. Targeted agents: the rules of combination. Clinical Cancer Research. 2007; 13(18): 5232–5237.
23.    Billingham ME, Mason JW, Bristow MR, Daniels JR . Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treatment Reviews. 1978; 62(6): 865–872 .
24.    Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM . Modulation of anthracycline-induced myofi brillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation. 2002; 105(13): 1551–1554 .
25.    Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Seminars in Oncology. 2006; 33(3): 2–7.
26.    Edward TH, Courtney LB. Cardiovascular Complications of Cancer Therapy Incidence, Pathogenesis, Diagnosis, and Management. Journal of the American College of Cardiology. 2009; 53(24): 2232-2247.
27.    Armenian SH, Xu L, Ky B, et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. Journal of Clinical Oncology. 2016; 34(10): 1122–1130.
28.    Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. European Heart Journal. 2013; 34(15): 1102–1111.
29.    Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010; 10(2): 337.
30.    Harbeck N, Ewer MS, Laurentiis M, Suter TM. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Annals of Oncology. 2011; 22(6): 1250–1258.
31.    Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Seminars in Oncology. 1998; 25(4): 72– 85.
32.    Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008; 94(2): 525–33.
33.    Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. British Journal of Haematology. 2005; 131(5): 561–578.  
34.    Pritchard K, Shepherd L, Andrulis I, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. New England Journal of Medicine. 2006; 354(8): 2103-2111.
35.    Goldenberg M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clinical therapeutics. 1999;21(2):309–318.
36.    Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005; 104(2): 2492–2498.
37.    Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). European Journal of Cancer. 2005; 41(1): 1542–1546.
38.    Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 128(5): 240–319.
39.    Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. Journal of Clinical  Oncology. 2005; 23(1): 792–799.
40.    Barbey JT, Soignet S. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Annals of Internal Medicine. 2001; 135(3): 842–843.
41.    Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Safety. 2000; 22(2): 263–302.
42.    Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Annals of Internal Medicine. 1993; 118(6): 31–36.
43.    Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Review in Cancer. 2007; 7(6):332–344.
44.    Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. Journal of  Clinical Oncology. 2005; 23(11): 7811–7819.
45.    Ewer MS, O’Shaughnessy JA. Cardiac toxicity of trastuzumabrelated regimens in HER2-overexpressing breast cancer. Clinical Breast Cancer. 2007; 7(3): 600–607.
46.    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine. 2005; 353(9): 1673–1684.
47.    Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008; 118(15): 84 –95.
48.    Gianni L, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovascular Toxicology. 2007; 7(1): 67–71.
49.    Guglin M, Cutro R, Mishkin JD. Trastuzumab-induced cardiomyopathy. Journal of Cardiac Failure. 2008; 14(4): 437–444.
50.    Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Medicine. 2002; 8(17): 459–65.
51.    Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Procedings of National Academies Sciences U S A. 2002; 99(4): 8880-8885.
52.    Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy. 1997; 17(12): 729–736.
53.    Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol. 2002; 13(6): 484–485.
54.    Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. Journal of Cancer Research and Clinical Oncology. 2008; 134(3): 75–82.
55.    Saif MW, Tomita M, Ledbetter L, Diasio RB. Capecitabine-related cardiotoxicity: recognition and management. Journal of Supportive Oncology. 2008; 6(6): 41–48.
56.    Arbea L, Coma-Canella I, Martinez-Monge R, Garcia-Foncillas J. A case of capecitabine-induced coronary microspasm in a patient with rectal cancer. World Journal of Gastroenterology. 2007; 13(3): 2135–1237.
57.    Sestito A, Sgueglia GA, Pozzo C, et al. Coronary artery spasm induced by capecitabine. Journal of Cardiovascular Medicine. 2006; 7(4): 136–138.
58.    Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with taxol. Journal of National Cancer Institute. 1993; 4(5): 117–130.
59.    Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of National Cancer Institute. 2007; 99(11): 1232–1239.
60.    Sugrue MM, Yi J, Purdie D, Dong W, Grothey A, Kozloff M, and the BRiTE Study Investigators. Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV): results from the BRiTE registry. Journal of Clinical Oncology. 2007; 25(18): 4136.
61.    Kamba T, McDonald DM. Mechanisms of adverse effects of anti- VEGF therapy for cancer. British Journal of Cancer. 2007; 96(9): 1788–1795.
62.    Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. Journal of Clinical Oncology. 2003; 21(4): 3542.
63.    Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Current Hypertensive Report. 2007; 9(7): 320–328.
64.    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine. 2004; 350(13): 2335–2342.
65.    Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis. 2004; 7(8): 193–201.
66.    Yusuf SW, Razeghi P, Yeh ET. The diagnosis and management of cardiovascular disease in cancer patients. Current Problems in Cardiology. 2008; 33(9): 163–196.
67.    Rajkumar SV. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clinic Proceeding. 2005; 80(3): 1549–1551.
68.    Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008; 22(7): 414–423.
69.    Fahdi IE, Gaddam V, Saucedo JF, et al. Bradycardia during therapy for multiple myeloma with thalidomide. American Journal of Cardiology. 2004; 93(5): 1052–1055.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available